Coreline Soft said it has signed a contract to supply AVIEW COPD, an automated lung image analysis software for the diagnosis of chronic obstructive pulmonary disease (COPD), to Pulmonx Corporation in the U.S.

AVIEW COPD is a fully automated solution that combines the various image analysis algorithms required to diagnose COPD. It can analyze lung parenchyma, bronchi, air traps, and blood vessels, and has the ability to automate the segmentation process of bronchi and lung lobes fully.

The software has already been adopted by leading hospitals in major countries, including China and Japan.

According to Coreline, Pulmonx is a leading global company focused on minimally invasive treatments for lung diseases, including emphysema, which is a type of COPD, with the company’s headquarters located in Redwood City, California.

Pulmonx has published various clinical trials and efficacy data for minimally invasive medical devices and lung diseases targeting respiratory disorders, including the Zephyr valve, which was developed to treat breathing difficulties associated with severe emphysema.

Through the agreement with Pulmonx, Coreline Soft intends to strengthen its product sales based on its proprietary technology for lung disease diagnostics.

According to the World Health Organization (WHO), COPD is already the third leading cause of death in 2020 after cardiovascular disease and stroke.

Some health experts even predict COPD will become the number one cause of death worldwide by 2050.